Molecular Weight(MW): 247.25
Emtricitabine (FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.
Purity & Quality Control
Choose Selective Reverse Transcriptase Inhibitors
|Description||Emtricitabine (FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.|
Emtricitabine moderately reduces hepatocyte proliferation independent of effects on mtDNA in HepG2 human hepatoma cells. Emtricitabine plus tenofovir slightly reduced cell proliferation without affecting mitochondrial parameters.  Emtricitabine efficiently converts to their active metabolites in PBMCs and CEM cells. Emtricitabine combined with Tenofovir displays additive to synergistic activity against HIV replication in PBMCs and results in strongly synergistic anti-HIV activity in MT-2 cells against both wild-type and mutant virus.  Emtricitabine demonstrates antiviral activity against laboratory adapted strains of HIV-1 and HIV-2 in various cell system. Emtricitabine also exhibits antiviral activity in cell culture against feline and simian immuno-deficiency viruses (SIVs). Emtricitabine consistently exhibits up to 10-fold greater activity than lamivudine against all viruses tested in all T-cell lines. Emtricitabine generally demonstrates greater potency in vitro in human PBMCs than in MT-4 lines.  Emtricitabine also exhibits anti-HBV activity in vitro (EC50, 0.01–0.04 µM) that is comparable to the anti-HBV activity of 3TC.  Emtricitabine is approximately fourfold more active than 3TC in assays in the transformed T-cell line MT-4 infected with HIV-(1IIIB), whereas Zidovudine is more active than Emtricitabine. Emtricitabine, Lamivudine and Zidovudine are equally active against a panel of eight primary HIV-1 isolates from antiretroviral-naive subjects in PBMCs. 
-  Venhoff N, et al. Antivir Ther, 2007, 12(7), 1075-1085.
-  Borroto-Esoda K, et al. Antivir Ther, 2006, 11(3), 377-384.
-  Richman DD, et al. Antivir Ther, 2001, 6(2), 83-88.
|In vitro||DMSO||49 mg/mL (198.17 mM)|
|Water||49 mg/mL (198.17 mM)|
|Ethanol||9 mg/mL (36.4 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03789968||Enrolling by invitation||Drug: bictegravir/emtricitabine/tenofovir alafenamide||HIV/AIDS||Thomas Jefferson University|University of Maryland College Park|Indiana University Health|The Brooklyn Hospital Center|University of Illinois at Chicago|Nova Southeastern University|University of California San Francisco||September 1 2019||--|
|NCT03960645||Recruiting||Drug: B/F/TAF||HIV-1-infection||Gilead Sciences||June 28 2019||Phase 1|
|NCT03917420||Completed||Drug: Tenofovir 300Mg Oral Tablet|Drug: Emtricitabine 200 MG||HIV/AIDS||University of North Carolina Chapel Hill|National Institute of Allergy and Infectious Diseases (NIAID)||March 26 2019||Phase 4|
|NCT03706924||Completed||Drug: VM-1500FDC|Drug: Elpida®|Drug: Truvada®||HIV-1-infection||Viriom||June 1 2018||Phase 1|
|NCT03270969||Completed||Drug: Tenofovir Disoproxil Fumarate/Emtricitabine||HIV Prevention||University of Nebraska||January 5 2018||Phase 1|
|NCT03197961||Completed||Combination Product: tenofovir/emtricitabine|Drug: DMPA||HIV/AIDS|Contraception||Jessica Tarleton|University of Pittsburgh||November 17 2017||Early Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.